bioAffinity Technologies, Inc. (BIAF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, bioAffinity Technologies, Inc. (BIAF) has a cash flow conversion efficiency ratio of -0.352x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.56 Million) by net assets ($7.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BIAF net asset quality index to measure how much of total assets are equity-financed.
bioAffinity Technologies, Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how bioAffinity Technologies, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BIAF cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
bioAffinity Technologies, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of bioAffinity Technologies, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Volta Finance Ltd
LSE:VTAS
|
0.113x |
|
Amedeo Air Four Plus Limited
LSE:AA4
|
0.270x |
|
Olivers Real Food Ltd
AU:OLI
|
-0.053x |
|
Appulse Corp
V:APL
|
0.003x |
|
NEXTLEAF SOLUTIONS
F:L0MA
|
0.072x |
|
Easson Holdings Ltd
PA:MLEAS
|
N/A |
|
M&G Credit Income Investment Trust PLC
LSE:MGCI
|
0.028x |
|
Jost AG
MU:JOX
|
N/A |
Annual Cash Flow Conversion Efficiency for bioAffinity Technologies, Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of bioAffinity Technologies, Inc. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see BIAF market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.28 Million | $-9.33 Million | -1.282x | +54.09% |
| 2024-12-31 | $2.60 Million | $-7.26 Million | -2.792x | -124.51% |
| 2023-12-31 | $4.86 Million | $-6.04 Million | -1.244x | -237.35% |
| 2022-12-31 | $11.04 Million | $-4.07 Million | -0.369x | -384.08% |
| 2021-12-31 | $-15.79 Million | $-2.05 Million | 0.130x | -11.41% |
| 2020-12-31 | $-15.07 Million | $-2.21 Million | 0.146x | -76.26% |
| 2019-12-31 | $-4.04 Million | $-2.49 Million | 0.617x | -- |
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology t… Read more